Quality of anticoagulation with warfarin across Kuwait

Hellenic Journal of Cardiology

Volumn 54, Issue 2, 2013, Pages 102-106

  Zubaid, Mohammad ^a   Saad, Hisham ^b   Ridha, Mustafa ^c   Nair, Krishnan Kumar Mohanan ^c   Rashed, Wafa ^b   Alhamdan, Rashed ^d   Alene, Fahad ^a   Maghami, Marjan ^e   Sadek, Ali ^f  

^a KUWAIT UNIVERSITY   (Kuwait)

^b Mubarak Alkabeer Hospital   (United Arab Emirates)

^c Department of Medicine   (United Arab Emirates)

^d Aljahra hospital   (United Arab Emirates)

^e Boehringer Ingelheim   (United Arab Emirates)

^f MINISTRY OF HEALTH   (Kuwait)

Author keywords

Atrial fibrillation; Oral anticoagulation; Rosendaal TTR

Indexed keywords

WARFARIN;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; DIABETES MELLITUS; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RETROSPECTIVE STUDY;

EID: 84878185109     PISSN: 11099666     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Hart RG, Benavente O, McBride R, Pearce LA. Antithrom-botic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999; 131: 492-501.
2. Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006; 114: e257-e354.
3. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace. 2010; 12: 1360-1420.
4. Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med. 2003; 349: 1019-1026.
5. Connolly SJ, Pogue J, Eikelboom J, et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation. 2008; 118: 2029-2037.
6. Kalra L, Yu G, Perez I, Lakhani A, Donaldson N. Prospective cohort study to determine if trial efficacy of anticoagula-tion for stroke prevention in atrial fibrillation translates into clinical effectiveness. BMJ. 2000; 320: 1236-1239.
7. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briët E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993; 69: 236-239.
8. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994; 154: 1449-1457.
9. Savelieva I, Bajpai A, Camm AJ. Stroke in atrial fibrillation: update on pathophysiology, new antithrombotic therapies, and evolution of procedures and devices. Ann Med. 2007; 39: 371-391.
10. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kan-nel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998; 98: 946-952.
11. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian Atrial Fibrillation Anticoagulation (CA-FA) Study. J Am Coll Cardiol. 1991; 18: 349-355.
12. SPAF Investigators. Stroke Prevention in Atrial Fibrillation. Final Results Circulation. 1991; 84: 527-539
13. Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheu-matic Atrial Fibrillation Investigators. N Engl J Med. 1991; 327: 1406-1412
14. Schmitt L, Speckman J, Ansell J. Quality assessment of an-ticoagulation dose management: comparative evaluation of measures of time-in-therapeutic range. J Thromb Thrombol-ysis. 2003; 15: 213-216.
15. van Walraven C, Jennings A, Oake N, Fergusson D, Forster AJ. Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest. 2006; 129: 1155-1166.
16. White HD, Gruber M, Feyzi J, et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med. 2007; 167: 239-245.
17. Connolly SJ, Pogue J, Eikelboom J, et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation. 2008; 118: 2029-2037.
18. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrom-botic therapy to prevent stroke in patients who have nonval-vular atrial fibrillation. Ann Intern Med. 2007; 146: 857-867.
19. Birman-Deych E, Radford MJ, Nilasena DS, Gage BF. Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation. Stroke. 2006; 37: 1070-1074.
20. Melamed OC, Horowitz G, Elhayany A, Vinker S. Quality of anticoagulation control among patients with atrial fibrillation. Am J Manag Care. 2011; 17: 232-237.
21. Zubaid M, Rashed WA, Alsheikh-Ali AA, et al. Gulf Survey of Atrial Fibrillation Events (Gulf SAFE): design and baseline characteristics of patients with atrial fibrillation in the Arab Middle East. Circ Cardiovasc Qual Outcomes. 2011; 4: 477-482.